We use cookies on our site to analyze traffic, enhance your experience, and provide you with tailored content.
For more information visit our privacy policy.Common Contracts
28 similar Change of Control Agreement contracts by Poniard Pharmaceuticals, Inc., Neorx Corp, Procyte Corp /Wa/
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED CHANGE OF CONTROL AGREEMENTChange of Control Agreement • March 16th, 2009 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Change of Control Agreement (this “Agreement”), dated as of February 24, 2009, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 13 hereof, the “Company”), and CHENI KWOK (the “Executive”) to reflect amendments made in December, 2008.
Standard Contracts
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED CHANGE OF CONTROL AGREEMENTChange of Control Agreement • March 16th, 2009 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Change of Control Agreement (this “Agreement”), dated as of February 24, 2009, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 13 hereof, the “Company”), and ANNA WIGHT (the “Executive”) to reflect amendments made in December, 2008.
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED CHANGE OF CONTROL AGREEMENTChange of Control Agreement • March 16th, 2009 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Change of Control Agreement (this “Agreement”), dated as of February 24, 2009, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 13 hereof, the “Company”), and RONALD A. MARTELL (the “Executive”) to reflect amendments made in December, 2008.
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED CHANGE OF CONTROL AGREEMENTChange of Control Agreement • March 16th, 2009 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Change of Control Agreement (this “Agreement”), dated as of February 24, 2009, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 13 hereof, the “Company”), and JANET R. REA (the “Executive”) to reflect amendments made in December, 2008.
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED CHANGE OF CONTROL AGREEMENTChange of Control Agreement • March 16th, 2009 • Poniard Pharmaceuticals, Inc. • Pharmaceutical preparations
This Amended and Restated Change of Control Agreement (this “Agreement”), dated as of February 24, 2009, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 13 hereof, the “Company”), and ROBERT L. DE JAGER (the “Executive”) to reflect amendments made in December, 2008.
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED CHANGE OF CONTROL AGREEMENT (CEO)Change of Control Agreement • May 8th, 2008 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Amended and Restated Change of Control Agreement (CEO) (this “Agreement”), dated as of March 3, 2008, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (formerly known as NeoRx Corporation and as supplemented by Section 13, the “Company”), and GERALD MCMAHON (the “Executive”).
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED CHANGE OF CONTROL AGREEMENT (SENIOR EXECUTIVE)Change of Control Agreement • May 8th, 2008 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Amended and Restated Change of Control Agreement (Senior Executive) (this “Agreement”), dated as of March 3, 2008, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (formerly known as NeoRx Corporation and as supplemented by Section 13, the “Company”), and RONALD MARTELL (the “Executive”).
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED CHANGE OF CONTROL AGREEMENT (VP)Change of Control Agreement • May 8th, 2008 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Amended and Restated Change of Control Agreement (VP) (this “Agreement”), dated as of March 3, 2008, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (formerly known as NeoRx Corporation and as supplemented by Section 13, the “Company”), and DAVID KARLIN (the “Executive”).
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED CHANGE OF CONTROL AGREEMENT (VP)Change of Control Agreement • May 8th, 2008 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Amended and Restated Change of Control Agreement (VP) (this “Agreement”), dated as of March 3, 2008, 2008, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (formerly known as NeoRx Corporation and as supplemented by Section 13, the “Company”), and ANNA WIGHT (the “Executive”).
PONIARD PHARMACEUTICALS, INC. AMENDED AND RESTATED CHANGE OF CONTROL AGREEMENT (SENIOR EXECUTIVE)Change of Control Agreement • May 8th, 2008 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Amended and Restated Change of Control Agreement (Senior Executive) (this “Agreement”), dated as of March 3, 2008, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (formerly known as NeoRx Corporation and as supplemented by Section 13, the “Company”), and CAROLINE LOEWY (the “Executive”).
PONIARD PHARMACEUTICALS, INC. CHANGE OF CONTROL AGREEMENTChange of Control Agreement • February 11th, 2008 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Change of Control Agreement (this “Agreement”), dated as of February 1, 2008, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 13, the “Company”), and Robert L. De Jager (the “Executive”).
PONIARD PHARMACEUTICALS, INC. CHANGE OF CONTROL AGREEMENTChange of Control Agreement • August 9th, 2007 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Change of Control Agreement (VP) (this “Agreement”), dated as of May 7, 2007, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 13, the “Company”), and Ronald A. Martell (the “Executive”).
PONIARD PHARMACEUTICALS, INC. CHANGE OF CONTROL AGREEMENTChange of Control Agreement • May 10th, 2007 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Change of Control Agreement (VP) (this “Agreement”), dated as of May 7, 2007, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 13, the “Company”), and Ronald A. Martell (the “Executive”).
PONIARD PHARMACEUTICALS, INC. CHANGE OF CONTROL AGREEMENT (VP)Change of Control Agreement • August 14th, 2006 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Change of Control Agreement (VP) (this “Agreement”), dated as of July 24, 2006, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 13, the “Company”), and Alan B. Glassberg, M.D. (the “Executive”).
PONIARD PHARMACEUTICALS, INC. CHANGE OF CONTROL AGREEMENT (VP)Change of Control Agreement • June 23rd, 2006 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Change of Control Agreement (VP) (this “Agreement”), dated as of June 23, 2006, is entered into by and between PONIARD PHARMACEUTICALS, INC., a Washington corporation (as supplemented by Section 13, the “Company”), and Caroline M. Loewy (the “Executive”).
PONIARD PHARMACEUTICALS, INC. CHANGE OF CONTROL AGREEMENT (VP)Change of Control Agreement • June 23rd, 2006 • Poniard Pharmaceuticals, Inc. • In vitro & in vivo diagnostic substances
This Change of Control Agreement (VP) (this “Agreement”), dated as of July 1, 2006, is entered into by and between PONIARD PHARMACEUTICALS, INC. (formerly NeoRx Corporation), a Washington corporation (as supplemented by Section 13, the “Company”), and Cheni Kwok (the “Executive”).
NEORX CORPORATION CHANGE OF CONTROL AGREEMENTChange of Control Agreement • June 29th, 2005 • Neorx Corp • In vitro & in vivo diagnostic substances
This Change of Control Agreement (this “Agreement”), effective as of JUNE 23, 2005, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 13, the “Company”), and David A. Karlin (the “Executive”).
NEORX CORPORATION CHANGE OF CONTROL AGREEMENTChange of Control Agreement • October 19th, 2004 • Neorx Corp • In vitro & in vivo diagnostic substances
This Change of Control Agreement (this “Agreement”), dated as of October 25, 2004, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 13, the “Company”), and Susan D. Berland (the “Executive”).
CHANGE OF CONTROL AGREEMENTChange of Control Agreement • August 12th, 2004 • Procyte Corp /Wa/ • Pharmaceutical preparations
This Change of Control Agreement (this “Agreement”), dated as of July 1, 2004, is between PROCYTE CORPORATION, a Washington corporation (the “Company”), and JOHN F. CLIFFORD (the “Executive”).
CHANGE OF CONTROL AGREEMENTChange of Control Agreement • August 12th, 2004 • Procyte Corp /Wa/ • Pharmaceutical preparations
This Change of Control Agreement (this “Agreement”), dated as of July 1, 2004, is between PROCYTE CORPORATION, a Washington corporation (the “Company”), and ROBIN L. CARMICHAEL (the “Executive”).
CHANGE OF CONTROL AGREEMENTChange of Control Agreement • August 12th, 2004 • Procyte Corp /Wa/ • Pharmaceutical preparations
This Change of Control Agreement (this “Agreement”), dated as of July 1, 2004, is between PROCYTE CORPORATION, a Washington corporation (the “Company”), and ROBERT W. BENSON (the “Executive”).
NEORX CORPORATION CHANGE OF CONTROL AGREEMENTChange of Control Agreement • August 9th, 2004 • Neorx Corp • In vitro & in vivo diagnostic substances
This Change of Control Agreement (VP) (this “Agreement”), dated as of May 11, 2004, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 13, the “Company”), and GERALD MCMAHON (the “Executive”).
NEORX CORPORATION CHANGE OF CONTROL AGREEMENT (CEO)Change of Control Agreement • February 23rd, 2004 • Neorx Corp • In vitro & in vivo diagnostic substances
THIS CHANGE OF CONTROL AGREEMENT (CEO) (this "Agreement"), dated as of February 19, 2004, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 13, the "Company"), and JACK L. BOWMAN (the "Executive").
NEORX CORPORATION CHANGE OF CONTROL AGREEMENTChange of Control Agreement • February 23rd, 2004 • Neorx Corp • In vitro & in vivo diagnostic substances
This Change of Control Agreement (VP) (this "Agreement"), dated as of February 28, 2003, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 13, the "Company"), and Linda Findlay (the "Executive").
NEORX CORPORATION CHANGE OF CONTROL AGREEMENTChange of Control Agreement • February 23rd, 2004 • Neorx Corp • In vitro & in vivo diagnostic substances
This Change of Control Agreement (VP) (this "Agreement"), dated as of February 28, 2003, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 13, the "Company"), and Anna Wight (the "Executive").
NEORX CORPORATION CHANGE OF CONTROL AGREEMENTChange of Control Agreement • February 23rd, 2004 • Neorx Corp • In vitro & in vivo diagnostic substances
This Change of Control Agreement (VP) (this "Agreement"), dated as of February 28, 2003, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 13, the "Company"), and Melinda Kile (the "Executive").
NEORX CORPORATION CHANGE OF CONTROL AGREEMENT (CEO/COO)Change of Control Agreement • May 15th, 2003 • Neorx Corp • In vitro & in vivo diagnostic substances
THIS CHANGE OF CONTROL AGREEMENT (CEO/COO) (this “Agreement”), dated as of February 12, 2003, is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 13, the “Company”), and DOUG B. GIVEN, M.D., Ph. D. (the “Executive”).
NEORX CORPORATION CHANGE OF CONTROL AGREEMENT (VP)Change of Control Agreement • March 29th, 2002 • Neorx Corp • In vitro & in vivo diagnostic substances
This Change of Control Agreement (VP) (this “Agreement”), dated as of , 20 , is entered into by and between NEORX CORPORATION, a Washington corporation (as supplemented by Section 13, the “Company”), and (the “Executive”).